Goldman Sachs raised the firm’s price target on TG Therapeutics to $13 from $12 and keeps a Neutral rating on the shares. The company’s Q4 earnings beat reflected sustained progress across commercial and clinical priorities, the analyst tells investors in a research note. The firm further notes that TG Therapeutics reported over 1,000 new Briumvi prescriptions in the quarter from over 640 healthcare prescribers across over 400 centers, illustrating its “increased breadth and depth of launch”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
- TG Therapeutics announces issuance of additional patents for BRIUMVI
- TG Therapeutics announces European launch of BRIUMVI
